CDXS — Codexis, Inc.

Summary of Codexis, Inc. (CDXS) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $70.4 million for 2025, up from $59.3 million in 2024, primarily driven by a $37.8 million technology transfer agreement with Merck.
• Q4 Revenue: $38.9 million, reflecting growth from previous year’s $21.5 million.
• Product Gross Margin: Maintained at 64% for both Q4 and the full year, an improvement from 56% in the prior year.
• Net Income: Reported at $9.6 million for 2025, a turnaround from a net loss of $10.4 million in 2024.
• Cash Position: Ended 2025 with $78.2 million in cash, expected to fund operations through 2027.

2. Strategic Updates and Business Highlights

• ECOsynthesis Platform: Focused on RNA medicine, with significant progress in developing the ECOsynthesis manufacturing platform for siRNA production.
• Technical Milestones: Successfully synthesized 10 grams of commercially relevant siRNA and scaled production to 100 grams, aiming for half a kilo by year-end 2026.
• Partnerships: Signed three CDMO agreements with Bachem, Nitto Avecia, and Axolabs, exceeding the goal of one agreement for 2025.
• Innovation: Introduced stereochemical control in siRNA synthesis, potentially enhancing product potency and purity.
• Operational Improvements: Modernized production infrastructure and achieved ISO 9001 certification, enhancing quality assurance for customers.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to range between $72 million to $76 million, with a heavier weighting towards the second half of the year.
• Operational Focus: Plans to continue scaling the ECOsynthesis platform and begin construction on a GMP facility in the second half of 2026, operational by the end of 2027.
• Market Potential: The total addressable market for siRNA production technologies is projected to reach $2 billion in five years.

4. Bad News, Challenges, or Points of Concern

• Cost Management: A one-time restructuring charge of $3.4 million was incurred in Q4 due to a workforce realignment aimed at reducing operating costs.
• Speculative Revenue: A portion of the 2026 revenue guidance remains speculative, as it is based on historical customer buying practices.
• Dependence on ECOsynthesis: While the legacy biocatalysis business is stable, the company is pivoting towards ECOsynthesis, which may introduce risks if the new technology does not gain traction as expected.

5. Notable Q&A Insights

• Stereoisomer Control: Management is actively exploring the biological impact of stereoisomer control, with expectations to present data at the TIDES meeting.
• Contractual Progression: The initial contract for 50 grams of siRNA is a prototype for future agreements, with potential for larger contracts as products move into clinical trials.
• Revenue Visibility: Management indicated that while there is a solid base of expected revenue, the early part of the year carries uncertainty regarding new contracts and customer commitments.

Overall, Codexis, Inc. showcased a strong financial turnaround in 2025, with promising advancements in their ECOsynthesis platform and strategic partnerships, while also navigating challenges related to cost management and revenue predictability.